Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy
05:09 EDT 2 Jul 2012 | thePharmaLetter
In a second accord between the US biotech companies this year, Biogen Idec (Nasdaq: BIBB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into an exclusive, worldwide option and collaboration agreement under which they will develop and commercia..
Original Article: Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy
More From BioPortfolio on "Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
